Lawrence Park

Medical Officer / Psychiatrist at the National Institute of Mental Health (NIMH), NIH

Data updated

Papers

5 publications

Trials

0 clinical trials

Links

Research Footprint

Lawrence Park appears in 5 tracked papers (2017–2020), most studied alongside Ketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Neuroimaging & Brain Measures.

Most-cited paper: Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine (467 citations).

Frequent co-authors: Carlos Zarate, Evan Ballard and Mark John Niciu.

Background & Research

Lawrence T. Park is a psychiatrist and clinical researcher at the National Institute of Mental Health’s Experimental Therapeutics and Pathophysiology Branch. His publications focus on ketamine’s antidepressant and antisuicidal effects, including sleep, dissociation, and neurophysiological predictors of response. He has also coauthored broader reviews on ketamine and serotonergic psychedelics in rapid-acting antidepressant research.

Key Impact

He is a clinician-scientist whose work on ketamine, suicidality, and rapid-acting antidepressant mechanisms has helped shape psychiatric research on psychedelic-adjacent therapeutics.

5

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

9 collaborators· click a node to visit their profile

Full network →

Affiliations

Institutions, companies, and organisations Lawrence Park is associated with.